STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer, Trial City

IndustrySTATOct 15, 2026

Also covered by: Clinical Trials Arena

Trial results

How does this affect your work day to day?

No comments yet.

Join the discussion